Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Valve | 13 | 2018 | 47 | 2.280 |
Why?
|
| Bioprosthesis | 10 | 2018 | 55 | 1.740 |
Why?
|
| Heart Valve Prosthesis Implantation | 8 | 2018 | 41 | 1.420 |
Why?
|
| Cardiac Surgical Procedures | 9 | 2013 | 71 | 1.340 |
Why?
|
| Heart Valve Prosthesis | 9 | 2018 | 53 | 1.330 |
Why?
|
| Cardiopulmonary Bypass | 9 | 2012 | 57 | 1.080 |
Why?
|
| Coronary Artery Bypass | 9 | 2013 | 100 | 1.070 |
Why?
|
| Pulmonary Artery | 3 | 2012 | 23 | 0.740 |
Why?
|
| Heart Valve Diseases | 5 | 2015 | 25 | 0.680 |
Why?
|
| Myocardial Ischemia | 3 | 2015 | 83 | 0.640 |
Why?
|
| Prosthesis Design | 6 | 2018 | 87 | 0.630 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2011 | 21 | 0.630 |
Why?
|
| Esophagus | 2 | 2015 | 22 | 0.600 |
Why?
|
| Coronary Disease | 3 | 2007 | 200 | 0.600 |
Why?
|
| Aortic Valve Insufficiency | 7 | 2018 | 24 | 0.590 |
Why?
|
| Larynx | 1 | 2015 | 19 | 0.550 |
Why?
|
| Congenital Abnormalities | 1 | 2015 | 10 | 0.550 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 24 | 0.540 |
Why?
|
| Trachea | 1 | 2015 | 55 | 0.530 |
Why?
|
| Postoperative Complications | 7 | 2013 | 670 | 0.520 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2012 | 4 | 0.510 |
Why?
|
| Echocardiography, Transesophageal | 6 | 2012 | 40 | 0.490 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 45 | 0.480 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 226 | 0.480 |
Why?
|
| Cognition Disorders | 2 | 2007 | 390 | 0.450 |
Why?
|
| Aortic Aneurysm | 2 | 2010 | 12 | 0.450 |
Why?
|
| Humans | 42 | 2018 | 29093 | 0.440 |
Why?
|
| Antifibrinolytic Agents | 2 | 2013 | 16 | 0.430 |
Why?
|
| Aged | 24 | 2018 | 9487 | 0.430 |
Why?
|
| Female | 30 | 2018 | 18164 | 0.430 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2017 | 134 | 0.430 |
Why?
|
| Middle Aged | 23 | 2018 | 10829 | 0.410 |
Why?
|
| Male | 31 | 2018 | 17807 | 0.400 |
Why?
|
| Chymases | 3 | 2017 | 28 | 0.400 |
Why?
|
| Embolism, Cholesterol | 1 | 2011 | 6 | 0.400 |
Why?
|
| Sinus of Valsalva | 1 | 2010 | 2 | 0.390 |
Why?
|
| Mitral Valve | 3 | 2011 | 28 | 0.390 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2015 | 11 | 0.380 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 2 | 2007 | 7 | 0.360 |
Why?
|
| Ventricular Function, Left | 1 | 2011 | 194 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 464 | 0.350 |
Why?
|
| Heart Diseases | 2 | 2010 | 97 | 0.350 |
Why?
|
| Aorta, Thoracic | 2 | 2006 | 72 | 0.330 |
Why?
|
| Aprotinin | 2 | 2005 | 6 | 0.330 |
Why?
|
| Angiotensin II | 3 | 2015 | 279 | 0.330 |
Why?
|
| Aortic Valve Stenosis | 4 | 2018 | 28 | 0.330 |
Why?
|
| Treatment Outcome | 15 | 2018 | 3099 | 0.310 |
Why?
|
| Heart Valves | 2 | 2005 | 15 | 0.310 |
Why?
|
| Follow-Up Studies | 9 | 2012 | 2108 | 0.310 |
Why?
|
| Reoperation | 6 | 2011 | 203 | 0.310 |
Why?
|
| Aneurysm, Dissecting | 2 | 2004 | 12 | 0.300 |
Why?
|
| Risk Factors | 9 | 2018 | 3531 | 0.280 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2005 | 7 | 0.270 |
Why?
|
| Adult | 15 | 2013 | 8420 | 0.260 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3111 | 0.260 |
Why?
|
| Time Factors | 7 | 2018 | 2001 | 0.250 |
Why?
|
| Aneurysm, False | 2 | 2015 | 13 | 0.240 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 3717 | 0.230 |
Why?
|
| Equipment Failure Analysis | 1 | 2002 | 42 | 0.220 |
Why?
|
| Angiotensinogen | 3 | 2017 | 73 | 0.210 |
Why?
|
| Vascular Surgical Procedures | 2 | 2017 | 91 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2015 | 598 | 0.200 |
Why?
|
| Postoperative Hemorrhage | 3 | 2013 | 38 | 0.190 |
Why?
|
| Cardiac-Gated Imaging Techniques | 2 | 2012 | 13 | 0.190 |
Why?
|
| Endocarditis | 2 | 2012 | 11 | 0.190 |
Why?
|
| Infant | 2 | 2015 | 969 | 0.190 |
Why?
|
| Atherosclerosis | 1 | 2006 | 693 | 0.180 |
Why?
|
| Prosthesis Failure | 2 | 2018 | 43 | 0.180 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2012 | 68 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2012 | 871 | 0.170 |
Why?
|
| Hypertension | 2 | 2017 | 906 | 0.170 |
Why?
|
| Stents | 2 | 2018 | 171 | 0.170 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 24 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2017 | 44 | 0.150 |
Why?
|
| Aorta | 2 | 2011 | 103 | 0.150 |
Why?
|
| Animals | 8 | 2017 | 7297 | 0.150 |
Why?
|
| Swine | 3 | 2009 | 201 | 0.140 |
Why?
|
| Tracheotomy | 1 | 2015 | 1 | 0.140 |
Why?
|
| Severity of Illness Index | 4 | 2007 | 863 | 0.140 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 182 | 0.130 |
Why?
|
| Heart Atria | 1 | 2015 | 62 | 0.130 |
Why?
|
| Hemodynamics | 4 | 2018 | 148 | 0.130 |
Why?
|
| Hospital Mortality | 3 | 2006 | 186 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2017 | 422 | 0.120 |
Why?
|
| Factor IX | 1 | 2013 | 8 | 0.120 |
Why?
|
| Age Factors | 2 | 2007 | 1108 | 0.110 |
Why?
|
| Preoperative Care | 3 | 2012 | 110 | 0.110 |
Why?
|
| Angiotensin I | 1 | 2015 | 262 | 0.110 |
Why?
|
| Length of Stay | 3 | 2017 | 292 | 0.110 |
Why?
|
| Mitral Valve Stenosis | 1 | 2012 | 8 | 0.110 |
Why?
|
| Echocardiography, Doppler | 2 | 2010 | 39 | 0.110 |
Why?
|
| Probability | 3 | 2007 | 150 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2012 | 136 | 0.100 |
Why?
|
| Dexmedetomidine | 1 | 2011 | 8 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 27 | 0.100 |
Why?
|
| Propofol | 1 | 2011 | 19 | 0.100 |
Why?
|
| Heart Aneurysm | 1 | 2011 | 3 | 0.100 |
Why?
|
| Heart Failure | 1 | 2017 | 568 | 0.100 |
Why?
|
| Survival Rate | 3 | 2010 | 795 | 0.100 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 113 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 2011 | 95 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2010 | 9 | 0.090 |
Why?
|
| Bioreactors | 1 | 2009 | 59 | 0.090 |
Why?
|
| Constriction | 2 | 2005 | 12 | 0.080 |
Why?
|
| Intraoperative Care | 2 | 2012 | 48 | 0.080 |
Why?
|
| Premedication | 1 | 2008 | 10 | 0.080 |
Why?
|
| Atrial Fibrillation | 2 | 2015 | 311 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2008 | 17 | 0.080 |
Why?
|
| Prognosis | 3 | 2010 | 1362 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2009 | 179 | 0.080 |
Why?
|
| Surgical Instruments | 1 | 2007 | 20 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 82 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2011 | 1167 | 0.080 |
Why?
|
| Saphenous Vein | 1 | 2007 | 20 | 0.070 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2007 | 10 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 186 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2008 | 2019 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2007 | 72 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 379 | 0.070 |
Why?
|
| Logistic Models | 2 | 2005 | 727 | 0.070 |
Why?
|
| Hematocrit | 1 | 2005 | 23 | 0.070 |
Why?
|
| Postoperative Period | 1 | 2006 | 91 | 0.070 |
Why?
|
| Causality | 1 | 2005 | 37 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2005 | 80 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 37 | 0.070 |
Why?
|
| North Carolina | 2 | 2010 | 1423 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2005 | 82 | 0.070 |
Why?
|
| Heart Rate | 1 | 2007 | 315 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 273 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2005 | 103 | 0.060 |
Why?
|
| Cattle | 1 | 2004 | 100 | 0.060 |
Why?
|
| Polyethylene Terephthalates | 1 | 2004 | 3 | 0.060 |
Why?
|
| Pericardium | 1 | 2004 | 50 | 0.060 |
Why?
|
| Insulin | 2 | 2005 | 346 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 637 | 0.060 |
Why?
|
| Comorbidity | 1 | 2005 | 540 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2007 | 865 | 0.060 |
Why?
|
| Suture Techniques | 1 | 2004 | 56 | 0.060 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2003 | 6 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2004 | 136 | 0.060 |
Why?
|
| Tissue Engineering | 1 | 2009 | 608 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2003 | 42 | 0.060 |
Why?
|
| Enoxaparin | 1 | 2003 | 19 | 0.060 |
Why?
|
| Heart Arrest, Induced | 1 | 2003 | 3 | 0.060 |
Why?
|
| Hemostatics | 1 | 2003 | 12 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2003 | 16 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2003 | 64 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2002 | 7 | 0.060 |
Why?
|
| Pre-Eclampsia | 1 | 2003 | 53 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 39 | 0.050 |
Why?
|
| Cesarean Section | 1 | 2003 | 82 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2012 | 1305 | 0.050 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2003 | 90 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 366 | 0.050 |
Why?
|
| Incidence | 1 | 2005 | 1119 | 0.050 |
Why?
|
| Cause of Death | 1 | 2002 | 220 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 176 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2013 | 1687 | 0.050 |
Why?
|
| Echocardiography | 2 | 2015 | 140 | 0.040 |
Why?
|
| Academic Medical Centers | 2 | 2011 | 150 | 0.040 |
Why?
|
| Punctures | 1 | 2017 | 32 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2018 | 190 | 0.040 |
Why?
|
| Receptors, Angiotensin | 1 | 2017 | 77 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2010 | 440 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2017 | 168 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2017 | 332 | 0.040 |
Why?
|
| Child | 1 | 2002 | 2219 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2015 | 52 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 246 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 83 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 183 | 0.030 |
Why?
|
| Adolescent | 1 | 2002 | 3254 | 0.030 |
Why?
|
| Rodentia | 1 | 2014 | 10 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2014 | 84 | 0.030 |
Why?
|
| Chest Tubes | 1 | 2013 | 6 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 280 | 0.030 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2013 | 5 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2013 | 9 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 350 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 514 | 0.030 |
Why?
|
| Heart | 1 | 2014 | 161 | 0.030 |
Why?
|
| Sternotomy | 1 | 2012 | 3 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2012 | 20 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 248 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2012 | 49 | 0.030 |
Why?
|
| Radiography | 2 | 2004 | 353 | 0.030 |
Why?
|
| Angiography | 1 | 2012 | 75 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 525 | 0.020 |
Why?
|
| Critical Care | 1 | 2011 | 114 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 90 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 859 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2011 | 239 | 0.020 |
Why?
|
| Sheep | 1 | 2009 | 221 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 532 | 0.020 |
Why?
|
| Blood Volume | 1 | 2008 | 6 | 0.020 |
Why?
|
| Platelet Transfusion | 1 | 2008 | 16 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2007 | 18 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2008 | 32 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2007 | 30 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 726 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 896 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2005 | 159 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2004 | 4 | 0.020 |
Why?
|
| History, 17th Century | 1 | 2004 | 3 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2005 | 501 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2004 | 29 | 0.020 |
Why?
|
| Paraplegia | 1 | 2003 | 6 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 85 | 0.010 |
Why?
|
| Heparin | 1 | 2003 | 75 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 493 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 641 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 359 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 412 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 815 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2002 | 278 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2002 | 466 | 0.010 |
Why?
|